Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients

Study Overview
=================
Brief Summary
-----------------
This randomized phase I trial is studying the side effects and best dose of Se-methyl-seleno-L-cysteine in healthy adult men. Studying samples of blood, urine, and toenail clippings in the laboratory from healthy men receiving Se-methyl-seleno-L-cysteine may help doctors learn more about how Se-methyl-seleno-L-cysteine works in the body.

Detailed Description
-----------------
PRIMARY OBJECTIVES: I. To evaluate the toxicity of MSC, given to healthy adult males as a single oral dose. SECONDARY OBJECTIVES: I. To characterize the pharmacokinetics of single oral doses of MSC in healthy adult male volunteers. II. To evaluate the baseline selenium content of toenail clippings in healthy adult males. OUTLINE: This is a multicenter, randomized, placebo controlled, double blind, dose escalation study. Participants are randomized to 1 of 2 arms. Arm I: Participants receive oral placebo on day 1. Arm II: Participants receive oral Se-methyl-seleno-l-cysteine (MSC) on day 1. Cohorts of 5 participants receive escalating doses of MSC until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 5 or 2 of 10 patients experience dose-limiting toxicity. Participants undergo blood, urine, and toenail clipping collection for pharmacokinetic and correlative studies. Samples are analyzed for plasma protein levels of selenium for proteomic and gene expression, molecular fingerprinting by mass spectrometry, and RNA by gene array analysis. After completion of study treatment, participants are followed at 7-14 days and at 30 days.

Official Title
-----------------
Phase I Study of Single Oral Dose of Se-Methyl-Seleno-L-Cysteine (MSC) in Adult Men

Conditions
-----------------
Healthy, no Evidence of Disease

Intervention / Treatment
-----------------
* Drug: Se-methyl-seleno-L-cysteine
* Other: placebo
* Other: pharmacological study
* Other: laboratory biomarker analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Total body weight between 50 and 115 kg Hgb > 12 gm/dl Platelets > 100,000/μL ANC > 1000/μL Creatinine < 1.5 mg/dl SGPT and SGOT < 3 X the institutional upper limit of normal (ULN) Total bilirubin < 1.5 X the institutional ULN (subjects with a higher level of bilirubin due to a familial metabolism will be considered on an individual basis) Life expectancy greater than 2 years Male subjects must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and until study completion (i.e., at least two weeks after dose of study drug) Ability to understand and the willingness to sign a written informed consent document Agree to refrain from use of selenium supplements while on study Exclusion Criteria: Not willing to remain at RPCI, and in follow up, as required Presence of medical conditions, which in the opinion of the investigators, would compromise either the subject, or the integrity of the data Individuals with a history of active liver or kidney disease within the past 6 months Treatment with an investigational drug within 30 days prior to the dose of study drug Use of prescription or nonprescription drugs, vitamins, or herbal supplements known to change gastric acidity (e.g., H2-antagonists, proton pump inhibitors, antacids) within 3 days of study drug administration History of allergic reactions attributed to compounds of similar chemical or biologic composition to MSC (e.g. reaction to other selenium supplements) Subjects who have donated 1 unit of blood within 30 days prior to the first dose of MSC Subjects with a known history of heavy metal exposure, such as lead, mercury, of arsenic ECOG performance status > 1 AUA total symptom score > 10 (or any individual symptom score of greater than or equal to 4 will exclude the participant)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Arm I (placebo)<br>Participants receive oral placebo on day 1. | Other: placebo<br>* Given orally<br>* Other names: PLCB;Other: pharmacological study<br>* Correlative studies<br>* Other names: pharmacological studies;Other: laboratory biomarker analysis<br>* Correlative studies<br>|
| Experimental: Arm II (Se-methyl-seleno-L-cysteine)<br>Participants receive oral Se-methyl-seleno-l-cysteine (MSC) on day 1. Cohorts of 5 participants receive escalating doses of MSC until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 5 or 2 of 10 patients experience dose-limiting toxicity. | Drug: Se-methyl-seleno-L-cysteine<br>* Given orally<br>* Other names: MSC;Other: pharmacological study<br>* Correlative studies<br>* Other names: pharmacological studies;Other: laboratory biomarker analysis<br>* Correlative studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical toxicity in healthy adult male volunteers, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v3.0 | Summarized using descriptive statistics. | Up to 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characterization of the pharmacokinetics of MSC | Descriptive statistics calculated for each cohort, using established pharmacokinetic analysis methods. | Up to 24 hours post-dose | 
| Selenium levels in toenail samples | Summarized graphically. | Up to 24 hours post-dose |